+45.1%
ABNB vs MRNA
+511.3%
-466.2%
-17.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.8% | -2.2% | +0.4% | -1.7% |
| 7D | -4.0% | +5.5% | -9.4% | -4.1% |
| 30D | +19.3% | +158.7% | -139.4% | +11.3% |
| 3M | +36.1% | +182.1% | -146.1% | +24.5% |
| 6M | +34.2% | +151.8% | -117.6% | +24.2% |
| YTD | +34.1% | +393.6% | -359.5% | +15.4% |
| 1Y | +45.1% | +499.5% | -454.3% | +22.1% |
| All | +45.1% | +511.3% | -466.2% | +22.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling